Terence Hadley, MD; Benjamin Djulbegovic, MD, PhD
Patients with hemophilia B can be effectively treated with prothrombin complex concentrates (factor IX complex) that contain factors II, VII, IX, and X (1). A complication of therapy with factor IX complex is disseminated intravascular coagulation, attributed in part to activated factors in factor IX complex (2). We describe a patient with hemophilia B who developed disseminated intravascular coagulation while being treated with factor IX complex for a cerebellar hemorrhage. The patient's therapy was switched from factor IX complex to monoclonal antibody-purified factor IX (Mononine, Armour, Blue Bell, Pennsylvania), and the disseminated intravascular coagulation resolved.
Hadley T, Djulbegovic B. Disseminated Intravascular Coagulation after Factor IX Complex Resolved Using Purified Factor IX Concentrate. Ann Intern Med. ;115:621–622. doi: 10.7326/0003-4819-115-8-621
Download citation file:
© 2019
Published: Ann Intern Med. 1991;115(8):621-622.
DOI: 10.7326/0003-4819-115-8-621
Coagulopathies, Hematology/Oncology.
Results provided by: